McKesson Q1 Earnings Beat, But Bottom Line Hit by Noncontrolling Charges; Restructuring and Apollo Deal Advance
MCK sits 41% above its 52-week low of $637.
Summary
McKesson's fiscal Q1 revenue and adjusted EPS beat expectations, but GAAP earnings were weighed down by non-cash charges on redeemable noncontrolling interests. Restructuring costs surged as new efficiency programs were launched, while the Apollo deal for Medical-Surgical Solutions closed and capital returns remained aggressive.
Key Events · Earnings and Guidance · MCK
-
Revenue and Adjusted EPS Beat
Revenue of $105.38 billion and adjusted EPS of $9.93 exceeded consensus estimates, driven by market growth in North American Pharmaceutical and Oncology & Multispecialty segments.
-
GAAP EPS Dragged by Noncontrolling Interest Charges
Net income attributable to McKesson fell 22% to $614 million, or $5.15 per diluted share, primarily due to $374 million in non-cash redemption value adjustments on redeemable noncontrolling interests from Core Ventures and Medical-Surgical Solutions.
-
Restructuring Charges Surge
Restructuring, impairment, and related charges totaled $136 million, up from $47 million a year ago, as the company initiated new multi-year efficiency programs in Corporate and Prescription Technology Solutions.
-
Apollo Minority Investment in Medical-Surgical Solutions Closes
On June 1, 2026, Apollo Funds acquired a 13% stake in the Medical-Surgical Solutions business for $1.25 billion in convertible preferred equity, a key step in the planned separation of the segment.
Analysis · MCK · Trade & Services
McKesson delivered a strong top-line quarter with revenue of $105.4 billion and adjusted EPS of $9.93, both comfortably ahead of consensus. However, GAAP net income attributable to McKesson fell 22% to $614 million, dragged down by $374 million in non-cash redemption value adjustments on redeemable noncontrolling interests tied to the Core Ventures and Medical-Surgical Solutions transactions. The quarter also saw a sharp increase in restructuring charges to $136 million as the company launched new efficiency programs. On the strategic front, the $1.25 billion Apollo minority investment in Medical-Surgical Solutions closed, and the company continued its aggressive capital return, repurchasing $2.5 billion in stock and raising the dividend 15%. The results underscore the complexity of McKesson's portfolio transformation — strong underlying operating momentum is being partially obscured by accounting charges and separation costs.
At the time of this filing, MCK was trading at $896.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $102.7B. The 52-week trading range was $637.00 to $999.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.